Monday 7th May 2012
|Text too small?|
Synlait Milk, the Canterbury milk processor controlled by China’s Bright Dairy, has signed a deal to supply colostrum to ASX-listed biopharmaceutical company Immuron.
No value was put on the agreement. A spokesman for Synlait said his company planned a production run of the ‘hyperimmune colostrum’ in October. While the volumes would be small compared to Synlait’s total production, it was high-end in terms of value, said Synlait spokesman Michael Wan.
Immuron, which focusses on “oral immunotherapy treatments using dairy-derived antibody products for humans”, has a product for the prevention of diarrhoea, Travelan, on the market and several others in various stages of development, according to its statement.
“As Immuron embarks on an era of increased global distribution of Travelan and other products, it is imperative to have a partner able to accommodate the anticipated significant increase in supply capacity, chief executive Joe Baini said in the statement.
Shares of Immuron rose 5.9 percent to 1.8 Australian cents on the ASX today and have declined 66 percent this year.
Last month, the Melbourne-based company raised A$2 million via a A$1 million share placement and an underwritten A$1 million share purchase plan. Proceeds were to fund the rollout of Travelan and ongoing development of other products, it said at the time.
No comments yet
Refining NZ announces non-cash impairment
Ryman Healthcare COVID-19 update Victoria
Talisman Quarterly Activities Report to 30 June 2020
General Capital gives notice of Annual Meeting
Scales Corporation - Business Update
Fonterra Co-operative Group Global Dairy Update
Fonterra revises its 2019/20 and 2020/21 forecast Farmgate Milk Price ranges
Briscoe Group Limited Market update: 2nd Quarter Sales to 26 July 2020
thl market update - A frame work for 2021
Me Today - Outcome Of Share Purchase Plan Offer